Health Condition 1: N042- Nephrotic syndrome with diffuse membranous glomerulonephritis
Conditions
Interventions
Intervention1: Injection rituximab in low dose 100mg monthly: 100 mg In infusion monthly for 6 months till the response
Control Intervention1: injection rituximab: 1 gm IV infusion , 2 weeks apart ( s
Sponsors
Nizams Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: Biopsy proven Primary MN (with serum PL2AR positive) Anti - PL2AR levels more than fifteen and less than hundred and fifty No clinical and laboratory response to ACE/ARB therapy. KDIGO defined Moderate and Severe Primary MN CKD stages one two and three Nephrotic syndrome
Exclusion criteria
Exclusion criteria: Secondary cause of Membranous nephropathy Absence of Nephrotic syndrome KDIGO defined very severe PMN and life-threatening nephrotic complications Anti - PL2AR levels negative CKD STAGE four and five Pregnant females Concurrent use of any immunosuppression 3 months prior to study Lost to follow up Negative consent for the study Contraindications of immunosuppressive therapy (HIV, Hep B, Hep C)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in proteinuria complete and partial remission change in eGFR from baselineTimepoint: follow up till 1 year after end of intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| to see safety and efficacy of rituximab change in the anti-PLA2R levels Timepoint: follow up over 1 year after end of intervention | — |
Countries
India
Contacts
Public ContactSree Bhushan Raju
Nizams Institute of Medical Sciences
Outcome results
None listed